The CEBPE (CCAAT/Enhancer-Binding Protein Epsilon) antibody is a crucial tool for studying the role of the CEBPE transcription factor in cellular differentiation and immune regulation. CEBPE, a member of the C/EBP family of leucine zipper transcription factors, is predominantly expressed in myeloid cells, particularly during granulocyte maturation. It plays a pivotal role in neutrophil development, regulating genes involved in secondary granule formation, cell cycle arrest, and apoptosis. Dysregulation of CEBPE is linked to congenital neutrophil disorders, such as specific granule deficiency (SGD), characterized by impaired immune function.
CEBPE antibodies are widely used in research applications like Western blotting, immunofluorescence, and chromatin immunoprecipitation (ChIP) to detect protein expression, localization, and DNA-binding activity. These antibodies help elucidate mechanisms underlying granulopoiesis, inflammation, and hematological malignancies. Commercial CEBPE antibodies are typically raised against specific epitopes (e.g., human CEBPE amino acids 100-250) and validated for specificity across species (human, mouse, rat). Researchers rely on them to investigate CEBPE's interaction with regulatory networks, including its cross-talk with other transcription factors like PU.1 and RUNX1. Their utility extends to clinical studies exploring CEBPE mutations in rare genetic disorders and potential therapeutic targets for blood cancers.